Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.
Alcohol Drinking
/ adverse effects
Analysis of Variance
Chi-Square Distribution
Confidence Intervals
Cyclin-Dependent Kinase Inhibitor p16
/ metabolism
Esophageal Neoplasms
/ virology
Female
France
Human papillomavirus 16
Humans
Incidence
Logistic Models
Lung Neoplasms
/ virology
Male
Middle Aged
Neoplasms, Multiple Primary
/ epidemiology
Oropharyngeal Neoplasms
/ mortality
Retrospective Studies
Smoking
/ adverse effects
Squamous Cell Carcinoma of Head and Neck
/ mortality
Tertiary Care Centers
Cancer
Human papilloma virus
Oropharynx
Second primary neoplasia
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
28
07
2020
revised:
28
09
2020
accepted:
04
10
2020
pubmed:
1
11
2020
medline:
23
9
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Patients with oropharyngeal squamous cell carcinoma (OPSCC) display a significant risk of synchronous primary neoplasia (SPN) which could impact their management. The aims of this study were to evaluate the risk and distribution of SPN in OPSCC patients according to their HPV (p16) status, the predictive factors of SPN and the impact of SPN on therapeutic strategy and oncologic outcomes. All OPSCC patients treated from 2009 to 2014 were included in this multicentric retrospective study. Univariate analyses were conducted using Chi-2 and Fisher exact tests. For multivariate analyses, all variables associated with a p ≤ 0.10 in univariate analysis were included in logistic regression models. Among the 1291 patients included in this study, 75 (5.8%) displayed a SPN which was preferentially located in the upper aerodigestive tract, lung and esophagus. Comorbidity level (p = 0.03), alcohol (p = 0.005) and tobacco (p = 0.01) consumptions, and p16 tumor status (p < 0.0001) were significant predictors of SPN. In multivariate analysis, p16+ status was significantly associated with a lower risk of SPN (OR = 0.251, IC95% [0.133;0.474]). Patients with a SPN were more frequently referred for non-curative treatment (p = 0.02). In patients treated with curative intent, there was no impact of SPN on the therapeutic strategy (surgical vs. non-surgical treatment). We observed no overall survival differences between patients with or without SPN. P16 tumor status is the main predictive factor of SPN in OPSCC patients. This study provides crucial results which should help adapt the initial work-up and the global management of OPSCC patients.
Identifiants
pubmed: 33129057
pii: S1368-8375(20)30477-2
doi: 10.1016/j.oraloncology.2020.105041
pii:
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p16
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
105041Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.